What is Triptorelin
Triptorelin also was known as Gonadotropin-releasing hormone (GnRH) is a synthetic peptide that elicits the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) as a biological response of the gonadotropin-releasing hormone receptor through its interaction. This peptide is used to increase fertility and as a treatment for hormonally sensitive cancers.
How does it work?
Triptorelin is used in the suppression of spontaneous ovulation, which is a required component in vitro fertilization (IVF). Along with the release of FSH, triggers an oocyte release, which gives, as a result, the increase of pregnancy chances. When this peptide stimulates the production of LH and FSH from the pituitary, it is shown an increase in testosterone serum and an increase of sperm count in male or egg in females.
Results and benefits
Triptorelin can show effective results in the treatment of hormonally sensitive cancers like prostate cancer and breast cancer. A curable stage in prostate cancer occurs only when the disease is still inside the affected organs, but at the time that it spreads to the bones, it loses its efficacy. People using this peptide as a prostate cancer treatment should be aware of the risk of heart problems. In the case of breast cancer, hormonal blocking therapy reduces the production of estrogen that allows the growth of cancer.
When puberty occurs in an individual at an early age, it can cause adverse effects on the reduction of height potential and some lifelong health risks, along with psychological effects. Triptorelin can be used to delay puberty and prevent any of these events.
This peptide can manage dependent estrogen disorders like menorrhagia (an abnormal menstrual period in its quantity and duration), endometriosis (growth of uterine tissue outside the uterus), adenomyosis (growth of ectopic endometrial tissue within the myometrium) or uterine fibroids (benign smooth muscle tumors of the uterus).
Triptorelin can be useful in the treatment of congenital adrenal hyperplasia that involves abnormal production of sex steroids, which can cause vomiting, ambiguous genitalia, early pubic hair in childhood, early puberty and delayed puberty, menstrual irregularity, infertility and an enlarged clitoris, among others.
Is advised the use of Triptorelin previously to a cancer treatment on Women to reduce the risk of oocyte loss caused by chemotherapy, nevertheless the efficacy of this action is not proven and it should not be taken as an infallible precautionary measure.
The use of Triptorelin can cause hypoestrogenism (estrogen deficiency), which is manifested in hot flushes, headaches, and osteoporosis. Other patients have reported a change in bone density, that is why it required a continuous measurement of the bone mineral density levels in people that have been using this peptide for a long-term treatment.
People that have used this peptide prefer one single dose of 100 mcg per cycle of 4 months. Triptorelin dosage should be measured without falling in excess. It is important not to exceed 1 mg within a year due to Triptorelin doses in excess can inactivate the testes in the male because of a hyperstimulation of the pituitary.